biotherapy

(redirected from biotherapies)
Also found in: Dictionary, Encyclopedia.

modifier

 [mod´ĭ-fi-er]
1. an agent or method that causes something else to change.
biologic response modifier (BRM) (biological response modifier) a method or agent, such as a cytokine, monoclonal antibody, or vaccine, that alters host-tumor interaction. This is usually accomplished by amplifying the antitumor mechanisms of the immune system, but it also may be effected by mechanisms that affect host or tumor cell characteristics, either directly or indirectly. Called also biomodulator.
problem modifier on level three of the problem classification scheme of the omaha system, either of the two sets of terms used in conjunction with client problems, allowing the nurse to identify ownership of the problem and its degree of severity in relation to client interest, risk factors, and signs or symptoms.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

biotherapy

(bī′ō-thĕr′ə-pē)
n. pl. biothera·pies
Treatment of disease with biologics, such as certain drugs, vaccines, or antitoxins.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

biotherapy

A highly nonspecific term for any treatment of any condition with anything that is or was at some point alive.

Alternative medicine
The term biotherapy has been utilised by a number of complementary and alternative medicine providers and will have ad hoc definitions according to the purveyor of the individual therapy.

Mainstream medicine
(1) Immunotherapy, see there.
(2) Treatment with genetically engineered products.
(3) The use of organ extracts in managing a condition—e.g., thyroid tissue extracts.
(4) The International Biotherapy Society lists maggot debridement therapy, hirudotherapy, apitherapy and ichthiotherapy as forms of biotherapy.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Be The Match BioTherapies said Tmunity Therapeutics is working to create personalised next-generation immunotherapies for cancer and other diseases.
As stated previously, ACIP does not recommend the U.S.-licensed CSL Biotherapies' TIV, Afluria, for children aged <9 years (2,16) (Table).
* Cytokines and associated receptors are not only biomarkers for novel biotherapies but can assist in diagnosis of high disease activity in RA.
The CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend that CSL Biotherapies" trivalent influenza vaccine (TIV), sold under the trade name Afluria in the United States, not be used in young children, because it was associated with a large increase in the risk of fevers and febrile seizures in children in Australia and New Zealand.
"We appreciate that new influenza strains like the swine flu can surprise us with properties that mean they might require higher dosing and two injections rather than one to provoke the desired level of immune response in humans," Dr Russell Basser, CSL Biotherapies' global director of clinical development, said.
The federal government awarded a contract to CSL Biotherapies to supply H1N1 influenza vaccine material.
VACCINE TRADE NAME MANUFACTURER TIV Fluzone Sanofi Pasteur TIV Fluvirin Novartis Vaccines TIV Fluarix GlaxoSmithKline TIV FluLaval GlaxoSmithKline TIV Afluria CSL Biotherapies LAIV FluMist MedImmune VACCINE HOW SUPPLIED CONTENT TIV 0.25-mL prefilled 0 syringe 0.5-mL prefilled 0 syringe 0.5-mL vial 0 5-mL multidose vial 25 TIV 5-mL multidose vial 25 0.5-mL prefilled [less than syringe or equal to] 1 TIV 0.5-mL prefilled [less than syringe or equal to] 1 TIV 5-mL multidose vial 25 TIV 0.5-mL prefilled 0 syringe 5-mL multidose vial 24.5 LAIV 0.2-mL sprayer 0 TABLE 4 Increased flu activity in the community?
Amongst other monoclonal antibody biotherapies, Hans-Peter Hartung (Dusseldorf, Germany) outlined the promising results obtained with the monoclonal antibody anti CD20, rituximab, in a Phase II trial in RRMS patients and mentioned two new Phase III trials with this treatment, one in RRMS patients and more interestingly one in primary-progressive (PP) MS patients.
"This is the first published study of phages working against multidrug-resistant bacterial strains," says study coauthor Richard Carlton of Exponential Biotherapies in Port Washington, N.Y.
Formed as a jointly funded venture between Biotherapies, Inc.